Biomedical subjects

Modesto Orea Solano

Publications and source records attributed to Modesto Orea Solano.

8 recordsLinked to original sources

PubMedDate not supplied

[Aspirin induced asthma, urinary leukotriene E4 and zafirlukast].

OBJECTIVE: To evaluate the efficiency of zafirlukast in patients with aspirin-induced-asthma trough a measurement of VEF1, during the treatment and the symptoms daily reported. To evaluate the safety of treatment through a record of adversed events and laboratory and cabinet monitoring, to know the effect of zafirlukast on urine LTE4 level. MATERIAL AND METHODS: It was an open, controlled, prospective, longitudinal, observational study. Twenty patients with aspirin-induced asthma were included and 10 extrinsic asthma patients as a group control. On the aspirin-induced asthma, age range was between 28-82 years old patients with an average of 55. 17 female and three male and group control with demographic similar features. All patients were included in a 30 days wash period avoiding anti-inflammatory medication like steroids, cromons, etc., on the initial phase treatment. A determination of blood cell count, transaminases, bilirubins, immunoglobulins, GAME, electrocardiogram, thorax study and LTE4 urine analysis was carried out. Twice a day 20 mg. zafirlukast dosis was administered to both groups, VO, during eight weeks. A symptoms report diary was given to each of the patients. A weekly and beginning sphirometric was carried out along the study to determine VEF1. Same laboratory and cabinet variables were determined on the final checking. RESULTS: 17 patients from the study group were analyzed and 10 from control group, an improvement of 12% average was reported on final VEF1, in comparison to the basal for both groups (p < .001) having this relation with the clinic improvement in the diary symptoms report. LTE4 urine levels diminished in similar form on both groups. This reduction was important (p < .001). Just three limited slight cephalalgia cases were reported (7.9%). CONCLUSION: Asthmatic patients belonging to extrinsic or aspirin-induced asthma groups irrespectively showed an improvement from zafirlukast treatment on spirometric and clinic levels. No serious disadvantage was found associated to zafirlukast and side effects were slight after two months. In LTE4 level drop was found in urine, in possible relation with zafirlukast, interruption on the pulmonary chronic inflammatory process.

Adult↗

PubMedDate not supplied

[Apoptosis].

The apoptosis phenomenon was identified approximately 40 years ago. In 1972, Kerr coined the term of apoptosis (programmed cellular death) to indicate that this way of cellular death was related to organic damage; but in contrast to other ways of death characterized by active cellular necrosis, in this, there is very little tissular reaction surrounding apoptotic cells. Apoptosis refers to the morphologic findings characterized by cellular shrink, nuclear condensation, fading of the membrane and fragmentation of this in apoptotic bodies with changes that possibly guide to the phagocytosis of the affected cell. Although there is great advance on phagocytosis mechanisms, signaling roads and pathology findings; a little is known about the molecular ways of apoptosis, intervening a great quantity of genes, surface receptors of T and B cells; ligand/receptor of death systems (particularly CD95), receptor of the tumoural necrosis factor (TNF-R), several interleukins with antiapoptotic activity, (specially IL-2), costimulatory receptors such as CD28 and proteins of the family Bcl-2 also with antiapoptotic activity. However, at this moment, the attention is focused in the apoptosis signaling pathways mediated by caspases, from which, 14 are known. Apoptosis has an important biological role in the development and homeostasis of cellular populations and in the pathogenesis and expression of diseases' processes. An excessive or insufficient apoptosis contributes to the pathogenesis of a wide variety of ischemic, neurodegenerative, and autoimmune diseases and viral infections, besides of participating in the growth and regression of tumoural processes. This article presents a general outline of the different apoptosis signaling pathways, the integration of multiple involved genes and receptors and the participation in several diseases of this programmed cellular death, either in excess or insufficient.

Animals↗

PubMedDate not supplied

[Measurement of cytokines in patients with exercise-induced asthma treated with anti-leukotrienes].

BACKGROUND: Exercise-induced asthma is defined as the transient broncho-spasm, that occurs after 3 to 8 minutes of continuous exercise; one of two mechanisms are implicated: the first is given by a hyper-osmolar environment interchange with the warm respiratory air and the water loss, the second due to reactive hyperemia or bronchial blood vessels edema. OBJECTIVES: To determine the effectiveness and safety of Zafirlukast treatment in exercise induce asthma, and in mild and moderated persistent bronchial asthma. Evaluate the security with laboratory test IL-2, IL-4, INFg, and CD69, to determinate TH1 and Th2 cells, laboratory and thorax x-ray determinations before and after zafirlukast treatment in exercise induce asthma, plus the functional respiratory test, and assert the clinical and adverse reaction with Zafirlukast. MATERIAL AND METHODS: A open, prospective, longitudinal study. Challenge test on a treadmill for 8 minutes. Twenty patients from the Allergy Service at Lic. Adolfo López Mateos Hospital, ISSSTE, in México City, fifteen female and five males. Aged 15 to 35 years. There was a control group of ten healthy subjects with similar age and sex. The drug Zafirlukast was administered 20 mg twice a day for eight weeks, with patient's informed and signed consent. Laboratory test: Blood Cell count, transaminases, bilirubins A, G, M and E immunoglobulins thorax X-ray, electrocardiogram, functional respiratory test before and after treatment. RESULTS: Zafirlukast blocked exercise induced asthma in the early and late phases. There was a statistically significant improvement of a VEF-1 after exercise with a p > 0.001; furthermore, there was significant improvement in the mid-spiratory speed before the exercise with a p > 0.05. The mid-spiratory speed after the exercise, improved (p > 0.01). There were no collateral reactions, such as Churg-Strauss, only transitory headache in six and nauseas in two. There were no statistically significant changes in the cytokines assessment. CONCLUSIONS: There were no statistically significant changes in the cytokines assessments, in four cases the IL-4 decreased after the treatment. The anti-leukotriene improved the bronchospastic answer during the early and late phases, reducing the FEV-1, decreasing the recovering phase.

Adolescent↗

PubMedDate not supplied

[Gastroesophageal reflux disease in pediatric patients with asthma].

BACKGROUND: Nowadays, the gastroesophageal reflux is a predisposing factor for the development of asthmatic attacks. OBJECTIVE: To determine the prevalence of gastroesophageal reflux in pediatric patients with asthma of the Service of Allergy and Immunology at the Hospital Regional Lic. Adolfo López Mateos. MATERIAL AND METHODS: It was made an observational study from July 2000 to July 2001. Gastroesophageal gammagraphic and endoscopy (with taking of esophageal biopsy) were carried out to each of the patients in order to find out if there was gastroesophageal reflux. RESULTS: 112 patients with moderate persistent asthma (54 women and 58 men) were included and divided in three different age groups (group I, from 1 to 5 years old; group II, from 6 to 10 and III, from 11 to 16 years old). The prevalence of gastroesophageal reflux was 138, 100 and 93, respectively, being specially high in males. Differences in the prevalence among different groups were statistically significant between group I and II (p < 0.001) and between I and III (p < 0.001). Significant changes were not observed between group II and III (p = NS). CONCLUSIONS: The prevalence of gastroesophageal reflux the structured was high, situation directly related with the diagnostic suspicion in our asthmatic population.

Adolescent↗

PubMedDate not supplied

[New prospects for the treatment of systemic lupus erythematosus].

The systemic lupus erythematosus is a significant therapeutic challenge: Multiorgan involvement and a variable disease course, characterized by clinical exacerbations and remissions, make difficult to predict the outcome. Few products have been specifically developed for this affection, and most accepted therapies have not been tested in randomized controlled trials of systemic lupus erythematosus. A variety of biological agents under investigation as potential treatments for systemic lupus erythematosus are designed to interfere with specific immunologic responses, hopefully avoiding generalized immunosuppression. Agents, which interfere with T cell-B cell collaboration, such as CTLA-4-Ig and anti-CD154 ligand monoclonal antibodies, may result in long-term therapeutic benefit. Products designed to decrease production of anti-dsDNA antibodies or inhibit complement activation, may prevent immune complex deposition and ameliorate organ-specific manifestations, such as renal disease. More aggressive interventions include gene therapy and stem cell transplantation.

Abatacept↗

PubMedDate not supplied

[Lymphocyte apoptosis in atopic dermatitis treated with transfer factor].

BACKGROUND: Atopic dermatitis is an inflammatory dysfunction in whose physiopathology the lymphocytes T play an important role in the regulation of the inflammatory process. OBJECTIVE: To determine and to characterize the role of apoptosis of lymphocytes in patients with moderate to severe atopic dermatitis before and after treatment with transfer factor. MATERIAL AND METHODS: Fifteen patients with moderate to severe atopic dermatitis in a range of age from 5 to 45 were included in the study. Fifteen healthy subjects were taken as a control group. In all subjects it was determined the apoptosis of the lymphocytes by means of annexin and TUNEL techniques, as well as the expression of CD95 cells. The 15 patients with atopic dermatitis received treatment with transfer factor in stepped dose as follows: 1 U/day/5 doses, 1 U/week/3 doses, 1 U/15 days/2 doses, 1 U/30 days, until completing three months. At the end of this period new determinations were done to measure apoptosis of lymphocytes and PMN. At the beginning and at the end assessments of the severity in relation to the scale SCORAD were made. RESULTS: By means of both techniques no significant difference was found in the percentage of apoptotic lymphocytes between patients and control subjects. Differences of the expression of CD95 between patients and control subjects before and after treatment were not significant. There was a significant difference (p < 0.01) of severity from the beginning to the end of treatment with transfer factor in patients with atopic dermatitis. CONCLUSION: No significant differences of apoptosis of lymphocytes were found in patients with atopic dermatitis who received treatment and control subjects, neither before not after the treatment with transfer factor. It was verified the decrease in the severity of the symptoms related to the treatment with transfer factor.

Adolescent↗

PubMedDate not supplied

[Psychological, immunological, and endocrinological implications of atopic dermatitis].

BACKGROUND: The atopic dermatitis is a chronic disease with immunological alterations, neuro-immune-endocrine implications and repercussions in the psyche. OBJECTIVE: To determine the effectiveness of the use of psychological support in the treatment of atopic dermatitis. MATERIAL AND METHODS: This study included 20 patients (from 15 to 50 years old) with moderated and severe atopic dermatitis based on the Hanifin and Rafka modified criteria. They were classified in three groups of treatment: A) 10 patients with transfer factor and psychological support, B) 10 with transference factor without psychological support, C) 10 healthy individuals as a control group. At the beginning and ending of the analysis the degree of severity of the illness was determined using the SCORAD scale. RESULTS: There was a more statistically significant clinical improvement on group A than in group B, besides a decrease in anxiety and depression, at a laboratory level including hormonal behavior, without meaningful changes. CONCLUSIONS: It was demonstrated that the treatment with immune-modulator and psychological support on the moderated and severe atopic dermatitis improves the clinical and immunological evolution of this illness.

Adjuvants, Immunologic↗

PubMedDate not supplied

[Airway hyperreactivity in patients with allergic and non-allergic rhinitis].

BACKGROUND: Epidemiologically there is an association between allergic rhinitis and asthma due to a common inflammatory process. Asthma can affect 40% of the patients with rhinitis and 80% of asthmatics present rhinitis. The relationship between the two diseases is explained by the term of "a united airway". Some patients with allergic rhinitis have nonspecific bronchial hyper-responsiveness, specially during the exacerbation stage. These patients have a unique physiologic characteristic that differs from the asthmatic and healthy subjects developing bronchoconstriction not related to clinical bronchospasm, therefore, allergic rhinitis is considered a risk factor for the asthma development. OBJECTIVE: To determine if there is bronchial hyper-responsiveness in patients with allergic and not allergic rhinitis, by correlating with the eosinophilia in nasal mucosa. MATERIAL AND METHODS: We studied a total of 32 patients with an age range from 18 to 38 years, of both sexes (11 men and 17 women) of the Hospital Regional Lic. Adolfo Lopez Mateos, ISSSTE. They were submitted to clinical history, laboratory studies (blood count cell, serum IgE levels, eosinophils of nasal mucosa), roentgenograms (paranasal sinus and esophagus-gastroduodenal series) and allergy skin tests with 32 allergens. It was taken biopsy of nasal mucosa for the search of eosinophils and it was carried out bronchial challenge with distilled water. Twenty-eight patients concluded the study, they were divided in two groups: a group of 15 patients with diagnosis of allergic rhinitis and another group of 13 patients with diagnosis of non allergic rhinitis. RESULTS: Fifty-six spirometry studies were performed and only 4 patients (26.6%) with diagnosis of allergic rhinitis presented fall of the FEV1 in the bronchial challenge in comparison with the group of non allergic rhinitis in which there were no changes in the FEV1 later to the bronchial challenge. This difference was statistically significant (-4.3 and 0.15, respectively with a p < 0.0370, CI 95%). Moreover, only in the group of allergic rhinitis eosinophils were found in the biopsy of nasal mucosa (93.3%). CONCLUSIONS: Nonspecific bronchial hyper-responsiveness is present in patients with allergic rhinitis. The presence of nasal eosinophils is a persistent inflammation parameter suggesting the allergic origin in these patients.

Adult↗